LAMICTAL XR by GSK is mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. First approved in 2010.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
LAMICTAL XR is an extended-release oral tablet formulation of lamotrigine, a small-molecule anticonvulsant approved in 2010. The drug's precise mechanism remains unknown, but it is proposed to inhibit voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and modulating presynaptic release of excitatory amino acids. It is used to treat epilepsy and other neurological conditions requiring seizure management.
Product is entering loss-of-exclusivity phase with moderate competitive pressure (30%), signaling transition from growth-stage team investment toward lifecycle management and potential portfolio repositioning.
mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LAMICTAL XR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LAMICTAL XR roles are declining as the product approaches loss of exclusivity, with zero linked job openings currently available. Career opportunities on this asset are limited to defensive commercial strategies and maintenance-phase functions rather than growth-oriented positions.